Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Rodriguez
M A
MA
Department of Hematology, U.T.M.D. Anderson Cancer Center, Houston 77030, USA.
D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology*; D015080:Mesna / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D001613:beta 2-Microglobulin / Q000032:analysis
D001613:beta 2-Microglobulin; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D007770:L-Lactate Dehydrogenase; D015080:Mesna; D002945:Cisplatin; D007069:Ifosfamide; D008775:Methylprednisolone